Sage Journals: Discover world-class research

Abstract

Substantially more women than men develop multiple sclerosis (MS), but information about the effects of MS and gender-specific issues such as pregnancy, breastfeeding, menstruation and hormone use is lacking. A survey study of neurologists’ practice patterns was undertaken to elicit information about gender-specific topics and the use of disease-modifying MS therapies (DMT) including the interferons and glatiramer acetate (GA). A total of 147 surveys were returned. Half of respondents require patients to discontinue DMT during pregnancy, while 35% encourage discontinuation. Among those who allow patients to continue therapy, half consider GA to be safer during pregnancy than the interferons. Nearly 86% of respondents do not use DMT in patients who are breastfeeding. Among the 11% who actually prescribe during breastfeeding, most recommend GA. Neurologists generally leave the decision to breastfeed up to patients, and most refer patients to obstetrician/gynaecologists for counselling about contraception or hormone replacement therapy. The survey results described here provide insight into how neurologists manage reproductive health issues among women with MS.

Keywords

contraception glatiramer acetate interferons lactation multiple sclerosis pregnancy women's health

Get full access to this article

View all access options for this article.

References

Noonan CW , Kathman SJ , White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women . Neurology 2002; 58: 136-138 .

National Multiple Sclerosis Society . The MS information sourcebook. 2001. Retrieved 5 November, 2002, from: http://www.nationalmssociety.org/Sourcebook-Pregnancy.asp

Confavreux C , Hutchinson M , Hours MM , Cortinovis-Tourniaire P , Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group . N Engl J Med 1998; 339: 285-291 .

Code of Federal Regulations, Title 21, Volume 4, Parts 200- 299. Revised April 1, 1997. US Government Printing Office. 21CFR201.57; 22-23.

Betaseron® package information. Richmond, CA: Berlax Laboratories , 2002.

Shabas D , Weinreb H. Preventive healthcare in women with multiple sclerosis . J Womens Health Gend Based Med 2000; 9: 389-395 .

Weppner DM , Brownscheidle CM. The evaluation of the health care needs of women with disabilities . Prim Care Update Ob Gyns 1998; 5: 210-210 .

Zorgdrager A , De Keyser J. The premenstrual period and exacerbations in multiple sclerosis . Eur Neurol 2002; 48: 204-206 .

Haas J. High dose IVIG in the post partum period for prevention of exacerbations in MS . Mult Scler 2002; 6: S18-S20 .

10.

Orvieto R , Achiron R , Rotstein Z , Noy S , Bar-Hava I , Achiron A. Pregnancy and multiple sclerosis: a 2-year experience . Eur J Obstet Gynecol Reprod Biol 1999; 82: 191-194 .